One shudders to imagine how many hours the ASX’s compliance team spends reining in the speculative biotech end of the Australian bourse. The shit they pull there!
Take Cellmid, a company which until March had spent 12 years predominantly in the anti-ageing and hair-loss prevention business. Suddenly, they’re in the COVID-19 antibody testing game. Who isn’t?
Loading...
Joe Aston helmed The Australian Financial Review's Rear Window column from 2012 to 2023. Connect with Joe on Facebook and Twitter.
